Terni

• A Trial for relapsed and relapsed/refractory multiple myeloma patients Ended recruitment
  2023-506733-30-00 4 2019-05-16 Multiple Myeloma relapsed and/or refractory
• A randomized trial that compares Carfilzomib - Lenalidomide - Dexamethasone (KRd) versus Lenalidomide - Dexamethasone (Rd) in new diagnosed … Ended recruitment
  2024-513396-41-00 5 2019-05-15 PATIENTS WITH NEW DIAGNOSIS MULTIPLE MYELOMA WITH AGE >= 65 YEARS OR N
• A multicenter, open label, randomized phase II study comparing daratumumab combined with bortezomib-cyclophosphamide-dexamethasone (Dara-VCd … Ended recruitment
  2024-511781-37-00 4 2019-04-16 YOUNG PATIENTS AFFECTED BY MULTIPLE MYELOMA (MM) TO THE DIAGNOSIS ELIG
• Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Foll … Ended recruitment
  2023-509602-29-00 5 2019-02-11 Patients with Limited Stage Small-Cell Lung Cancer (LS-SCLC)
• A Study of combination of Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) compared to VELCADE, Lenalidomide, and … Ended recruitment
  2023-506125-10-00 5 2018-12-24 Multiple Myeloma
• KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treat … Ended recruitment
  2024-513912-89-00 10 2018-12-13 Primary Or Secondary (Post-PV MF or Post-ET-MF) Myelofibrosis (MF) Wit
• A trial to learn how well durvalumab and chemotherapy with or without tremelimumab work in adults with advanced cancer of the bladder or uri … Ended recruitment
  2024-510976-19-00 5 2018-11-30 Patients with Unresectable Locally Advanced or Metastatic Urothelial C
• A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subject … Ended recruitment
  2023-506112-40-00 5 2018-09-26 R/R Multiple Myeloma
• STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA (Dara-VM … Ended recruitment
  2024-512049-17-00 6 2018-09-05 Newly diagnosed MM patients >= 65 years old or ineligible for autologo
• A Phase 3 Study of Zanubrutinib (BGB-3111) Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocyt … Ended recruitment
  2023-509976-40-00 5 2018-05-28 Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
• Sustained treatment-free period in the course of a disease when symptoms become less severe in BCR-ABL+ chronic myeloid leukemia: a prospect … Ended recruitment
  2023-510434-83-00 6 2016-10-17 Chronic Myeloid Leukemia (CML) in Chronic Phase (CP)
• A randomized phase III multicenter trial assessing efficacy and toxicity of a combination of Rituximab and Lenalidomide (R2) vs Rituximab al … Ended recruitment
  2024-511640-11-00 5 2014-05-15 Follicular lymphoma
• Study to test new drug eftilagimod alfa (also known as efti) combined with standard marketed treatments (pembrolizumab and chemotherapy) in … Ended
  2024-513621-23-00 5 2025-04-18 Advanced/metastatic non-small cell lung cancer (NSCLC)
• Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants with Multiple System Atrophy Ended
  2023-504876-12-00 5 2023-10-25 Neurogenic Orthostatic Hypotension
• An extension of the orchestra (PD0053) study to learn how safe minzasolmin is and if it works long-term in participants with Parkinson’s dis … Ended
  2022-500424-30-00 4 2022-12-28 Parkinson’s disease
• Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Ended
  2024-514570-43-00 5 2022-01-24 Renal cell carcinoma
• A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects With Metastatic or Local … Ended
  2024-513870-23-00 5 2021-06-28 Locally Advanced or Metastatic Unresectable Urothelial Cancer
• A Study of Subcutaneous Nivolumab in Previously Treated Advanced or Metastatic Clear Cell Renal Cell Carcinoma Ended
  2023-503280-42-00 5 2021-06-01 Metastatic Clear Cell Renal Cell Carcinoma
• Study of Tislelizumab and/or Pamiparib Containing Treatments in Participants With Advanced Malignancies Ended
  2023-508883-31-00 5 2021-02-23 Solid tumors and hamatological malignancies
• Phase 3 Study of Pembrolizumab plus Enzalutamide in mCRPC Ended
  2022-500785-10-00 5 2019-08-23 Metastatic Castration-Resistant Prostate Cancer
• A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eli … Ended
  2022-501970-20-01 5 2019-06-07 Cis-eligible Muscle-invasive bladder cancer.
• A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, … Ended
  2023-509711-83-00 5 2017-10-27 Advanced or Metastatic Renal Cell Carcinoma
• Multicenter trial with carfilzomib combined with lenalidomide or cyclophopshamide with or without autologous transplant in newly diagnosed m … Ended
  2024-516630-35-01 4 2015-01-12 NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS ELEGIBLE FOR AUTOLOGOUS
• A Study to Compare the Efficacy and Safety of a Combined Regimen of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) Versus Obinutuzumab and … Ended
  2023-504034-22-00 5 2014-12-18 Chronic Lymphocytic Leukemia (CLL)

Showing 73–96 of 97 trials